In recent trading session, Novo Nordisk ADR (NYSE:NVO) saw 7.44 million shares changing hands at last check today with its beta currently measuring 0.63. Company’s recent per share price level of $64.35 trading at -$1.8 or -2.72% at last check today assigns it a market valuation of $216.61B. That most recent trading price of NVO’s stock is at a discount of -130.23% from its 52-week high price of $148.15 and is indicating a premium of 11.42% from its 52-week low price of $57.00.

For Novo Nordisk ADR (NVO), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 2.09. Splitting up the data highlights that, out of 5 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 4 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of 5.91 in the current quarter.

Novo Nordisk ADR (NYSE:NVO) trade information

Upright in the red during last session for losing -2.72%, in the last five days NVO remained trading in the red while hitting it’s week-highest on Monday, 05/12/25 when the stock touched $64.35 price level, adding 5.02% to its value on the day. Novo Nordisk ADR’s shares saw a change of -25.19% in year-to-date performance and have moved -2.16% in past 5-day. Novo Nordisk ADR (NYSE:NVO) showed a performance of 2.34% in past 30-days.

Wall Street analysts have assigned a consensus price target of 158 to the stock, which implies a rise of 59.27% to its recent value today. Analysts have been projecting 156 as a low price target for the stock while placing it at a high target of 160. It follows that stock’s current price would drop -142.42% in reaching the projected high whereas dropping to the targeted low would mean a loss of -142.42% for stock’s current value.

Novo Nordisk ADR (NVO) estimates and forecasts

This year revenue growth is estimated to rise 15.92% from the last financial year’s standing.

8 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 77.79B for the same. And 8 analysts are in estimates of company making revenue of 83.22B in the next quarter. Company posted 68.06B and 71.31B of sales in current and next quarters respectively a year earlier.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 21.74% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 26.00% while estimates for its earnings growth in next 5 years are of 19.17%.

Novo Nordisk ADR (NYSE:NVO)’s Major holders

JENNISON ASSOCIATES LLC is the top institutional holder at NVO for having 21.22 million shares of worth $3.03 billion. And as of 2024-06-30, it was holding 0.476 of the company’s outstanding shares.

The second largest institutional holder is FMR LLC, which was holding about 19.49 million shares on 2024-06-30. The number of shares represents firm’s hold over 0.4373 of outstanding shares, having a total worth of $2.78 billion.

On the other hand, Goldman Sachs TRT II-Goldman Sachs GQG Part. Intl Opportunities Fd. and HARBOR FUNDS-Harbor Capital Appreciation Fund are the top two Mutual Funds which own company’s shares. As of Jan 31, 2025 , the former fund manager was holding 4.82 shares of worth $307.36 million or 0.14% of the total outstanding shares. The later fund manager was in possession of 4.22 shares on Jan 31, 2025 , making its stake of worth around $268.98 million in the company or a holder of 0.12% of company’s stock.